ICD・CRTの考えかた　使いかた

出版社： 中外医学社
著者：
発行日： 2018-02-20
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784498136502
電子書籍版： 2018-02-20 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,260 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,260 円(税込)

購入する

商品紹介

ICD/CRTの使いかたや，そもそもの考えかたについて，医師やME，看護師などの初学者に向けて分かりやすくレクチャーした書．基礎編・応用編・特別編と別れた章立てで知識が体系的に身に付くように工夫され，読み物形式の解説は無理なく理解が深まるようにまとめられている．研修医からのQ&Aコーナーも充実しており，具体例を通じて臨床上の疑問も解決．基礎的知識から現場での応用力まで身に付く，心強いテキストである．

目次

  • 第1章　基礎編―ICD・CRTの考えかた―
    　1．ICD・CRT（D）の歴史と概要
    　2．仕組みと基本的設定
    　3．適応とガイドライン
    　4．植込み術・周術管理
    　5．管理・経過観察
    　6．特別基礎編

    第2章　応用編―ICD・CRTをより賢く使う―
    　1．ICDの考えかた
    　2．CRTの考えかた

    第3章　特別編―知って使う新しい除細動器―
    　　　　　　　（脱静脈内除細動リードシステム）
    　1．自動体外式除細動器（AED）
    　2．着用型自動除細動器（WCD）
    　3．皮下植込み型除細動器（S-ICD）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 基礎編 - ICD・CRTの考えかた -

P.12 掲載の参考文献
1) Kitamura T, Iwami T, Kawamura T, et al. Nationwide improvements in survival from out-of-hospital cardiac arrest in Japan. Circulation. 2012;126:2834-43.
PubMed
2) Preliminary report:effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial(CAST) Investigators. N Engl J Med. 1989;321:406-12.
 
3) Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303:322-4.
PubMed
4) Block M, Breithardt G. Optimizing defibrillation through improved waveforms. Pacing Clin Electrophysiol. 1995;18:526-38.
PubMed
5) Tanaka S. An overview of the fifth-generation implantable cardioverter defibrillator. Ann Thorac Cardiovasc Surg. 1998;4:303-11.
PubMed
6) Kouakam C, Kacet S, Hazard J-R, et al. Performance of a dual-chamber implantable defibrillator algorithm for discrimination of ventricular from supraventricular tachycardia. Europace. 2004;6:32-42.
PubMed
7) Stadler RW, Gunderson BD, Gillberg JM. An adaptive interval-based algorithm for withholding ICD therapy during sinus tachycardia. Pacing Clin Electrophysiol. 2003;26:1189-201.
PubMed
8) Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC) Developed with the special contribution of the Heart Failure Association(HFA) of the ESC. Eur Heart J. 2016;37:2129-200.
 
9) Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure:a report from the Italian network on congestive heart failure. Am Heart J. 2002;143:398-405.
PubMed
10) 奥村 謙. 不整脈の非薬物治療ガイドライン(2011年改訂版). Circ J. 2011.
 
11) Reynolds MR, Cohen DJ, Kugelmass AD, et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47:2493-7.
PubMed
12) Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the totally subcutaneous implantable defibrillator:2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol. 2015;65:1605-15.
PubMed
13) Troup PJ. Implantable cardioverters and defibrillators. Curr Probl Cardiol. 1989;14:673-843.
PubMed
P.26 掲載の参考文献
1) The Antiarrhythmics Versus Implantable Defibrillators(AVID) Investigators:A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-83.
 
2) Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators inpatients resuscitated from cardiac arrest:the Cardiac Arrest Study Hamburg(CASH). Circulation. 2000;102:748-54.
 
3) Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study(CIDS):a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-302.
PubMed
4) Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with animplanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.
 
5) Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of adefibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
PubMed
6) Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8. 312.
 
7) Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
 
8) 循環器病の診断と治療に関するガイドライン, 不整脈の非薬物治療ガイドライン(2011年改訂版). 2011.
 
9) Hammill SC, Packer DL, Stanton MS, et al. Termination and acceleration of vent-ricular tachycardia with autodecremental pacing, burst pacing, and cardioversion in patients with an implantable cardioverter defibrillator. Multicenter PCD Investigator Group. PACE. 1995;18:3-10.
 
10) Wathen MS, Sweeney MO, DeGroot PJ, et al, for the PainFREE Investigators. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. 2001;104:796-801.
PubMed
11) Wathen MS, DeGroot PJ, Sweeney MO, et al. for the Pain FREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous r11apid ventricular tachycardia in patients with implantable cardioverter-defibrillators:Pacing Fast Ventricular Tachycardia Reduces Shock Therapies(PainFREE Rx II) trial results. Circulation. 2004;110:2591-6.
 
P.41 掲載の参考文献
1) Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure(CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.
 
2) Koplan BA, Kaplan AJ, Weiner S, et al. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure. Is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009;53:355-60.
 
3) Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, et al. Effects of cardiac resynchronization therapy on overall mortality and mode of death:a meta-analysis of randomized controlled trials. Eur Heart J. 2006;27:2682-8.
 
4) 日本循環器学会合同研究班報告:不整脈の非薬物治療ガイドライン(2011年改訂版). <http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf.>
 
5) Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy(MADIT-CRT) trial. Circulation. 2011;123:1159-66.
PubMed
6) Mullens W, Grimm RA, Verga T, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53:765-73.
 
7) Martin DO, Lemke B, Birnie D, et al. Adaptive CRT Study Investigators. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy:results of the adaptive CRT trial. Heart Rhythm. 2012;9:1807-14.
 
8) Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing:analysis of the adaptive CRT trial. Heart Rhythm. 2013;10:1368-74.
PubMed
9) Brugada J, Delnoy PP, Brachmann J, et al. RESPOND CRT Investigators. Contractility sensor-guided optimization of cardiac resynchronization therapy:results from the RESPOND-CRT trial. Eur Heart J;2016. [Epub ahead of print]
 
10) Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. PARTNERS Study Investigators. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations:results from PARTNERS HF(Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure)study. J Am Coll Cardiol. 2010;55:1803-10.
 
11) Hindricks G, Taborsky M, Glikson M, IN-TIME study group. Implant-based multiparameter telemonitoring of patients with heart failure(IN-TIME):a randomised controlled trial. Lancet. 2014;384:583-90.
 
P.54 掲載の参考文献
1) 日本循環器学会. 不整脈の非薬物治療ガイドライン. <www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf>
 
2) Satomi K, Kurita T, Suyama K, et al. Catheter ablation of stable and unstable ventricular tachycardias in patients with arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2006;17:469-76.
PubMed
3) Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyo-pathy/dysplasia. Circulation. 2009;120:366-75.
 
4) Tannno K, Miyoshi F. et al. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J. 2015;69:19-22.
 
5) Daubert JP, Zareba W, Hall WJ, et al. MADIT II Study Investigators:Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial(MADIT) II patients. J Am Coll Cardiol. 2006;47:98-107.
PubMed
6) Zaman S, Narayan A, Thiagalingam A, et al. Long-term arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia after miyocardial infarction. Circulation. 2014;129:848-54.
 
7) Satake H, Fukuda K, Sakata Y, et al. Current Status of Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter Defibrillator in Patients With Chronic Heart Failure. A Report From the CHART-2 Study. Circ J. 2015;79:381-90.
PubMed
8) Takagi y, Yasuda S, Tsunoda R, et al. on behalf of the Japanese Coronary Spasm Association. Clinical Characteristics and Long-Term Prognosis of Vasospastic Angina Patients Who Survived Out-of-Hospital Cardiac Arrest. Multicenter Registry Study of the Japanese Coronary Spasm Association. Circ Arrhythmia and Electrophysiology. 2011;4:295-302.
 
9) Matsue Y, Suzuki M, Nishizaki M, et al. Clinical Implications of an Implantable Cardioverter-Defibrillator in Patients With Vasospastic Angina and Lethal Ventricular Arrhythmia. J Am Coll Cardiol. 2012;60:908-13.
PubMed
10) Take Y, Morita H, Toh N, et al. Identification of high-risk syncope related to ventricular fibrillation in patients with Brugada syndrome. Heart Rhythm. 2012;9:752-9.
PubMed
11) Kamakura S, Ohe T, Nakazawa K, et al. Long-Term Prognosis of Probands With Brugada-Pattern ST-Elevation in Leads V1-V3. Circ Arrhythm Electrophysiol. 2009;2:495-503.
PubMed
12) Brugada P, Geelen P, Brugada R, et al. Prognositic value of electrophysiologic investigation in Brugada syndrome. J Cardiovasc ELectrophysiol. 2001;12:1004-7.
 
13) Priori SG, Napolitano C, Gasparini M. et al. Natural history of Brugada syndrome:insights for risk stratification and management. Circulation. 2002;105:1342-7.
PubMed
14) Paul M, Gerss J, Schulze-Bahr E. et al. Role of programmed ventricular stimulation in patients with Brugada syndrome:a meta-analysis of worldwide published data. Eur H J. 2007;28:2126-33.
 
15) Giustetto C, Drago S, Demarchi PG, et al. Risk stratification of the patients with Brugada type electrocardiogram:a community-based prospective study. Europace. 2009;11:507-13.
 
16) Probst V, Veltmann C, Eckardt L. et al. Long-term prognosis of patients diagnosed with Brugada syndrome:Results from the FINGER Brugada Syndrome Registry. Circulation. 2010;121:5. 635-43.
PubMed
17) Makimoto H, Kamakura S, Aihara N, et al. Clinical impact of the number of extrastimuli in programmed electrical stimulation in patients with Brugada type 1 electro-cardiogram. Heart Rhythm. 2012;9:42-8.
 
18) Ruwald MH, Okumura K, Kimura T, et al. Syncope in high-risk cardiomyopathy patients with implantable defibrillators:frequency, risk factors, mechanisms, and association with mortality:results from the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy(MADIT-RIT) study. Circulation. 2014;129:5. 545-52.
PubMed
19) Kober L, Thune JJ, Nielsen JC, et al. Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375:13. 1221-30.
PubMed
P.74 掲載の参考文献
1) 奥村 謙, 他. 不整脈の非薬物治療ガイドライン(2011年改訂版). <http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf>
 
2) Abraham WT, Fisher WG, Smith AL, et al. MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-53.
 
3) Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure(COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
PubMed
4) Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure:the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure(COMPANION) trial. J Am Coll Cardiol. 2005;46:2329-34.
 
5) Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure(CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.
 
6) Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure[the CArdiac REsynchronization-Heart Failure(CARE-HF) trial extension phase]. Eur Heart J. 2006;27:1928-32.
PubMed
7) Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT(PROSPECT) trial. Circulation. 2008;117:2608-16.
PubMed
8) Linde C, Abraham WT, Gold MR, et al. REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-43.
 
9) Moss AJ, Hall WJ, Cannom DS, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.
 
10) Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy(MADIT-CRT) trial. Circulation. 2011;123:1159-66.
PubMed
11) Zareba W, Klein H, Cygankiewicz I, et al. MADIT-CRT Investigators. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy(MADIT-CRT). Circulation. 2011;123:1061-72.
 
12) Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370:1694-701.
PubMed
13) Tang AS, Wells GA, Talajic M, et al. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385-95.
 
14) Beshai JF, Grimm RA, Nagueh SF, et al. RethinQ Study Investigators. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007;357:2461-71.
 
15) Ruschitzka F, Abraham WT, Singh JP, et al. EchoCRT Study Group. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395-405.
 
16) Curtis AB, Worley SJ, Adamson PB, et al. Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block(BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585-93.
 
17) Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC) Developed with the special contribution of the Heart Failure Association(HFA) of the ESC. Eur Heart J. 2016;37:2129-200.
 
18) Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J. 2002;23:1780-7.
PubMed
19) Koplan BA, Kaplan AJ, Weiner S, et al. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure. Is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009;53:355-60.
 
20) Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation:a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239-46.
PubMed
P.96 掲載の参考文献
1) Greenspon AJ, Patel JD, Kurtz SM, et al. 16-Year Trends in the Infection Burden for Pacemakers and Implantable Cardioverter-Defibrillators in the United States. JACC. 2011;58:1001-6.
PubMed
2) Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascular implantable device infection in the United States:temporal trends and causative insights. PACE. 2010;33:414-9.
PubMed
3) 日本循環器学会, 他(班長:堀 正二). 循環器病の診断と治療に関するガイドライン(2008年度合同研究班報告)循環器疾患における抗凝固・抗血小板療法に関するガイドライン(2009年改訂版2015/10/7更新版). Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease(JCS 2009). 2009.
 
4) Birnie DH, Healey JS, Wells GA, et al. for the BRUISE CONTROL Investigators. Pacemaker or Defibrillator Surgery without Interruption of anticoagulation. N Engl J Med. 2013;368:2084-93.
 
5) Mangram AJ, Horan TC, Pearson ML, et al. the hospital infection control practices advisory committee. Guideline for Prevention of Surgical Site Infection. Infect Cont Hosp Epidermiol. 1999;20:250-78.
 
6) Klug D et al. for the PEOPLE Study Group. risk factors related to infections of implanted pacemakers and cardioverter-defibrillators:Results of a Large Prospective Study. Circulation. 2007;116:1349-55.
 
7) Imai K. Pocket creation in the prepectoral subfascial position for the implantation of a cardiac implantable electrical device. Journal of Arrhythmia. 2014;30:92-4.
 
8) Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction. Heart Rhythm. 2017;14:e503-51.
PubMed
P.105 掲載の参考文献
1) 石川利之. 心臓ペーシングのすべて 改訂2版. 東京:中外医学社;2012.
 
2) 石川利之, 中島 博, 編. 心臓デバイス植込み手技. 東京:南江堂;2011.
 
3) Healey JS, Hohnloser SH, Glikson M, et al. Cardiac defibrillator implantation without induction of ventricular fibrillation:a single-blind, non-inferiority, randomized controlled trial(SIMPLE). Lancet. 2015;385:785-91.
PubMed
P.106 掲載の参考文献
1) 米国疾病予防管理センターHP<http://www.cdc.gov/hai/>
 
2) 石川利之. 心臓ペーシングのすべて 改訂2版. 東京:中外医学社. 2012;p.167-8.
 
3) 石川利之, 中島 博, 編. 心臓デバイス植込み手技. 東京:南江堂. 2011;p.108.
 
P.109 掲載の参考文献
1) 石川利之. 心臓ペーシングのすべて 改訂2版. 東京:中外医学社;2012.
 
2) 石川利之, 中島 博, 編. 心臓デバイス植込み手技. 東京:南江堂;2011.
 
P.111 掲載の参考文献
1) 石川利之. 心臓ペーシングのすべて 改訂2版. 東京:中外医学社;2012.
 
2) 石川利之, 中島 博, 編. 心臓デバイス植込み手技. 東京:南江堂;2011.
 
P.114 掲載の参考文献
1) Cha EM, Khoury GH. Persistent left superior vena cava. Radiological and clinical significance. Radiology. 1972;103:375-81.
PubMed
2) 山内仁紫, 五味渕誠, 宇都宮英敏, 他. 左上大静脈遺残症(PLSVC)を合併する症例の経静脈ペースメーカー植え込み術の検討. 心臓ペーシング. 1986;2:22-5.
 
3) 石川利之. 心臓ペーシングのすべて 改訂2版. 東京:中外医学社;2012. p.152-3.
 
P.117 掲載の参考文献
1) Ramza BM, Rosenthal L, Hui R, et al. Safety and Effectiveness of placement of pacemaker and defibrillator leads in the axillary vein guided by contrast venography. Am J Cardiol. 1997;80:892-6.
PubMed
2) Chan NY, Liem LB, Mok NS, et al. Clinical experience of contrast venography guided axillary vein puncture in biventricular pacing R1. Int J Cardiol. 2003;92:55-8.
 
3) Harada Y, Katsume A, Kimata M, et al. Placement of pacemaker leads via the extrathoracic subclavian vein guided by fluoroscopy and venography in the oblique projection. Heart Vessels. 2005;20:19-22.
 
4) 中尾佳永, 榎木千春, 岡田隆之, 他. 炭酸ガス静脈造影法によるペースメーカー植込み術の経験. 日本心臓病学会誌. 2011;6:122-5.
 
5) Seto AH, Jolly A, Salcedo J. Ultrasound-guided venous access for pacemakers and defibrillators. J Cardiovasc Electrophysiol. 2013;24:370-4.
PubMed
6) Migliore F, Siciliano M, De Lazzari M, et al. Axillary vein puncture using fluoroscopic landmarks:a safe and effective approach for implantable cardioverter defibrillator leads. J Interv Card Electrophysiol. 2015;43:263-7.
 
7) Nakata A, Harada T, Kotntani K, et al. Extrathoracic subclavian venipuncture by using only the J-type guidewire for permanent pacemaker electrode placement. Int Heart J. 2013;54:129-32.
 
P.121 掲載の参考文献
1) 石川利之, 中島 博, 編. 心臓デバイス植込み手技. 東京:南江堂;2011. p.49-50.
 
2) 石川利之, 心臓ペーシングのすべて. 東京:中外医学社;2012. p.149.
 
3) 岡村英夫, 編. 今さら聞けないペースメーカ. 東京:メジカルビュー社;2015. p.129.
 
4) Migliore F, Siciliano M, Lazzari M, et al. Axillary vein puncture using fluoroscopic landmarks:a safe and effective approach for implantable cardioverter defibrillator leads. J Interv Card Electrophysiol. 2015;43:263-7.
PubMed
P.123 掲載の参考文献
1) De Voogt WG, Van Mechelen R, Van Den Bos A, et al. A technique of lead insertion for low atrial septal pacing. Pacing Clin Electrophysiol. 2005;28:639-46.
 
2) Acosta H, Pothula VR, Rodriguez M, et al. Placement of a pacing lead at the inferior portion of the interatrial septum without special tools. Pacing Clin Electrophysiol. 2007;30:Suppl1:S84-7.
 
3) Bailin SJ. Atrial lead implantation in the Bachmann bundle. Heart Rhythm. 2005;2:784-6.
PubMed
4) Nishii N, Kusano KF, Miyaji K, et al. Usefulness of a long-straight sheath for atrial lead insertion at the right atrial septum. Circ J. 2008;72:262-7.
PubMed
5) 林 祐次, 橋本 徹. 経静脈リード挿入法とペースメーカ植込みの実際. In:心臓リズムマネージメントを究める, 1版. 東京:メジカルビュー社;2009. p.116-20.
 
6) 井川 修. Alternative Pacingの実際と解剖学的知識. Therapeutic Research. 2010;31:171-7.
Medical*Online
P.126 掲載の参考文献
1) 石川利之, 中島 博, 編. 心臓デバイス植込み手技. 東京:南江堂;2011;p.74-82.
 
P.128 掲載の参考文献
1) Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-7.
 
2) Wilkoff, BL, Cook, JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. The dual chamber and VVI implantable defibrillator(DAVID)trial. JAMA. 2002;288:3115-23.
PubMed
3) Steinberg JS, Fischer A, Wang P, et al. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J Cardiovasc Electrophysiol. 2005;16:359-65.
 
4) Tantengco MV, Thomas RL, Karpawich PP. Left ventricular dysfunction afterlong-term right ventricular apical pacing in the young. J Am Coll Cardiol. 2001;37:2093-100.
 
5) Chan NY, Yuen HC, Choy CC, et al. Left ventricular volumes and systolic function after long-term right ventricular pacing may be predicted by paced QRS duration, but not pacing site. Heart Lung Circ. 2014;23:43-8.
 
6) Mizukami A, Matsue Y, Naruse Y, et al. Implications of right ventricular septal pacing for medium-term prognosis:Propensity-matched analysis. Int J Cardiol. 2016;220:214-8.
PubMed
7) Sarvari SI, Sitges M, Tolosana Viu JM, et al. Left ventricular dysfunction is related to the presence and extent of a septal flash in patients with right ventricular pacing. Europace. 2016 Mar 7(Epub ahead of print)
 
P.132 掲載の参考文献
1) Ebert M, Jander N, Minners J, et al. Long-Term impact of right ventricular pacing on left ventricular systolic function in pacemaker recipients with preserved ejection fraction:results from a large single-center registry. J Am Heart Assoc. 2016;5:e003485 doi:10.1161/JAHA.116.003485.
 
2) Kiehl EL, Makki T, Kumar R, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016;13:2272-8.
PubMed
3) Ahmed Mo, Gorcsan III Jo, Marek Jo, et al. Right ventricular apical pacing-induced left ventricular dyssynchrony is associated with a subsequent decline in ejection fraction. Heart Rhythm. 2014;11:602-8.
 
4) Zhang XH, Chen H, Siu CW, et al. New-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. J Cardiovasc Electrophysiol. 2008;19:136-41.
 
5) Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585-93.
PubMed
P.135 掲載の参考文献
1) Madhavan M, Samuel J. Mattheu A, et al. Implanting and Extracting Cardiac Devices:Technique and Avoiding Complications. In:David L, Hayes, and Paul A, Friedman. editors. Cardiac Pacing, Defibrillation and Resynchronization:A Clinical Approach. Third edition. John Wiley & Sons, Ltd;2013. p.176.
 
P.139 掲載の参考文献
1) Rozmus G, Daubert JP, Huang DT, et al. Venous thrombosis and stenosis after implantation of pacemakers and defibrillators. Journal of Interventional Cardiac Electrophysiology. 2005;13:9-19.
PubMed
2) Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction:heart rhythm society expert consensus on facilities, training, indications, and patient management. Heart Rhythm. 2009;6:1085-104.
PubMed
P.140 掲載の参考文献
1) Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction:Heart rhythm society expert consensus on facilities, training, indications, and patient management:this document was endorsed by the American Heart Association(AHA). Heart Rhythm. 2009;6:1085-104.
PubMed
P.143 掲載の参考文献
1) Leon AR, Delurgio DB, Mera F. Practical approach to implanting left ventricular pacing leads for cardiac resynchronization. J Cardiovascular Electrophysiol. 2005;16(1):100-5.
PubMed
P.144 掲載の参考文献
1) Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction:Heart rhythm society expert consensus on facilities, training, indications, and patient management:this document was endorsed by the American Heart Association(AHA). Heart Rhythm. 2009;6:1085-104.
PubMed
P.145 掲載の参考文献
1) Klug D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators:results of a large prospective study. Circulation. 2007;18:116(12):1349-55.
PubMed
P.149 掲載の参考文献
1) Transvenous lead extraction:Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management. Heart Rhythm. 2009;6:7.
PubMed
2) Tarakji KG et al. Cardiac implantable electronic device infections:presentation, management, and patient outcomes. Heart Rhythm. 2010;7(8):1043-7.
PubMed
P.150 掲載の参考文献
1) Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction:Heart rhythm society expert consensus on facilities, training, indications, and patient management:this document was endorsed by the American Heart Association(AHA). Heart Rhythm. 2009;6:1085-104.
PubMed
2) Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503-51.
PubMed
P.168 掲載の参考文献
1) 河野律子, 荻ノ沢泰司, 長友敏寿, 他. 就労とデバイス装着者とのかかわり. In:奥村 謙, 編. ペースメーカ・ICD・CRT/CRT-D-トラブルシューテイングからメンタルケアまで-. 東京:メディカルビュー社;2012. p.228-34.
 
2) 日本循環器学会(班長 奥村 謙). ペースメーカ, ICD, CRTを受けた患者の社会復帰・就学・就労に関するガイドライン(2013年改訂版). 日本循環器学会ホームページ<http://www.j-circ.or.jp/guideline/pdf/JCS2013_okumura_h.pdf>.
 
3) 堀江正知. 職場環境における産業保健対策. In:安部治彦, 豊島 健, 編. 生体内植込みデバイス患者と電磁干渉. 東京:メディカルレビュー社;2006. p.423-41.
 
4) 荻ノ沢泰司, 河野律子, 安部治彦. デバイス患者の社会復帰と医療従事者の果たす役割. 月刊循環器. 2013;3:(2). 92-100.
 
5) 藤本 裕. 職場環境による電磁干渉と対策. In:安部治彦, 豊島 健, 編. 生体内植込みデバイス患者と電磁干渉. 東京:メディカルレビュー社;2006. p.381-422.
 
6) 日本循環器学会. 心疾患患者の学校, 職域, スポーツにおける運動許容条件に関するガイドライン(2008年改訂版). In:日本循環器学会(班長 長嶋正實). 循環器病の診断と治療に関するガイドライン(2007年度合同研究班報告). 日本循環器学会ホームページ <http://www.j-circ.or.jp/guideline/pdf/JCS2008_nagashima_h.pdf>.
 
7) 日本医師会. 道路交通法に基づく一定の症状を呈する病気等にある者を診断した医師から公安委員会への任意の届出ガイドライン(平成26年9月). 日本不整脈学会ホームページ <http://jhrs.or.jp/pdf/com_device201409_01.pdf>.
 
8) Noda T, Kurita T, Nitta T, et al. Appropriate duration of driving restrictions after inappropriate therapy from implantable cardiac shock devices-interim analysis of the Nippon Storm Study. Circ J. 2014;78:1989-91.
PubMed
9) 渡邉英一, 他. ICD不適切作動と失神の発生率:シンポジウム「ICD患者の自動車運転制限～道路交通法改正と学会ステートメント～」. 日本不整脈学会・第7回植込みデバイス関連冬季大会. 2015年2月20日(東京).
 
10) 辻 善範, 他. ICD不適切抗頻拍ペーシング作動の帰結:致死性不整脈の誘因. 日本不整脈学会・第7回植込みデバイス関連冬季大会抄録集. p.175.
 
11) 日本不整脈学会. 道路交通法改正の概要について(平成26年5月). 日本不整脈学会ホームページ <http://jhrs.or.jp/pdf/com_device201405_01.pdf>.
 
P.186 掲載の参考文献
1) Abraham WT. Cardiac resynchronization therapy for heart failure:biventricular pacing and beyond. Curr Opin Cardiol. 2002;17:346-52.
PubMed
2) Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.
PubMed
3) Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
 
4) Nelson GS, Curry CW, Wyman BT, et al. Predictors of systolic augmentation from left ventricular preexcitation in patients with dilated cardiomyopathy and intraventricular conduction delay. Circulation. 2000;101:2703-9.
PubMed
5) Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-43.
PubMed
6) Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.
PubMed
7) Behar JM, Bostock J, Zhu Li AP, et al. Cardiac resynchronization therapy delivered via a multipolar left ventricular lead is associated with reduced mortality and elimination of phrenic nerve stimulation:Long-term follow-up from a multicenter registry. J Cardiovasc Electrophysiol. 2015;26:540-6.
 
8) Crossley GH, Exner D, Mead RH, et al. Chronic performance of an active fixation coronary sinus lead. Heart Rhythm. 2010;7:472-8.
PubMed
9) Crossley GH, Sorrentino RA, Exner DV, et al. Extraction of chronically implanted coronary sinus leads active fixation vs passive fixation leads. Heart Rhythm. 2016;13:1253-9.
PubMed
10) Keilegavlen H, Hovstad T, Faerestrand S. Active fixation of a thin transvenous left-ventricular lead by a side helix facilitates targeted and stable placement in cardiac resynchronization therapy. Europace. 2016;18:1235-40.
PubMed
11) Biffi M, Foerster L, Eastman W, et al. Effect of bipolar electrode spacing on phrenic nerve stimulation and left ventricular pacing thresholds:an acute canine study. Circ Arrhythm Electrophysiol. 2012;5:815-20.
PubMed
12) Mullens W, Grimm RA, Verga T, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53:765-73.
 
13) Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy:the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology(ESC). Developed in collaboration with the European Heart Rhythm Association(EHRA). Eur Heart J. 2013;34:2281-329.
 
14) Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing:analysis of the adaptive CRT trial. Heart Rhythm. 2013;10:1368-74.
PubMed
15) Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8:1469-75.
PubMed
16) Koplan BA, Kaplan AJ, Weiner S. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure:is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009;53:355-60.
 
17) Mullens W, Verga T, Grimm RA. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol. 2009;53:600-7.
PubMed
18) Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure:correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841-8.
PubMed
19) Vanderheyden M, Houben R, Verstreken S, et al. Continuous monitoring of intrathoracic impedance and right ventricular pressures in patients with heart failure. Circ Heart Fail. 2010;3:370-7.
PubMed
20) Bohm M, Drexler H, Oswald H, et al. Fluid status telemedicine alerts for heart failure:a randomized controlled trial. Eur Heart J. 2016;37:3154-63.
PubMed
21) Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. Pacing Clin Electrophysiol. 2009;32:363-70.
PubMed
22) Nishii N, Kubo M, Okamoto Y, et al. Decreased intrathoracic impedance associated with OptiVol alert can diagnose increased B-type natriuretic Peptide-MOMOTARO(Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization)Study. Circ J. 2015;79:1315-22.
PubMed
P.191 掲載の参考文献
1) Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760-5.
PubMed
2) Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009-17.
PubMed
3) Scott PA, Silberbauer J, McDonagh TA, et al. Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes:a meta-analysis. Heart Rhythm. 2014;11:828-35.
PubMed
4) Jimenez-Candil J, Hernandez J, Perdiguero P, et al. Prognostic significance of nonsustained ventricular tachycardia episodes occurring early after implantable cardioverter-defibrillator implantation among patients with left ventricular dysfunction. Am J Cardiol. 2016;118:1503-10.
PubMed
P.194 掲載の参考文献
1) Abraham WT, Compton S, Haas G, et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events:results of the Fluid Accumulation Status Trial(FAST). Congest Heart Fail. 2011;17:51-5.
PubMed
2) Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure:correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841-8.
PubMed
3) Conraads VM, Tavazzi L, Santini M, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations:the SENSE-HF trial. Eur Heart J. 2011;32:2266-73.
PubMed
4) van Veldhuisen DJ, Braunschweig F, Conraads V, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011;124:1719-26.
PubMed
5) Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations:results from PARTNERS HF(Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure)study. J Am Coll Cardiol. 2010;55:1803-10.
PubMed
P.197 掲載の参考文献
1) 日本循環器学会学術委員会合同研究班(班長 奥村 謙). ペースメーカ, ICD, CRTを受けた患者の社会復帰・就学・就労に関するガイドライン(2013年改訂版). <http://www.j-circ.or.jp/guideline/pdf/JCS2013_okumura_h.pdf>
 
P.201 掲載の参考文献
1) 石川利之, 中島 博, 編. 心臓デバイス植え込み手技. 東京:南江堂. 2011;p.94-102.
 
2) Gold MR, Peters RW, Johnson JW, et al. Complications associated with pectoral cardioverter-defibrillator implantation:comparison of subcutaneous and submuscular approaches. Worldwide Jewel Investigators. J Am Coll Cardiol. 1996;28:1278-82.
 
3) Kistler PM, Fynn SP, Mond HG, et al. The subpectoral pacemaker implant:it isn't what it seems. Pacing Clin Electrophysiol. 2004;27:361-4.
PubMed
P.204 掲載の参考文献
1) Osswald S, Cron T, Gradel C, et al. Closed-loop stimulation using intracardiac impedance as a sensor principle:correlation of right ventricular dP/dtmax and intracardiac impedance during dobutamine stress test. Pacing Clin Electrophysiol. 2000;23:1502-8.
PubMed
2) Malinowski K. Interindividual comparison of different sensor principles for rate adaptive pacing. Pacing Clin Electrophysiol. 1998;21:2209-13.
PubMed
3) Proietti R, Manzoni G, Di Biase L, et al. Closed loop stimulation is effective in improving heart rate and blood pressure response to mental stress:report of a single-chamber pacemaker study in patients with chronotropic incompetent atrial fibrillation. Pacing Clin Electrophysiol. 2012;35:990-8.
PubMed
P.206 掲載の参考文献
1) Krum H1, Lemke B, Birnie D, et al. A novel algorithm for individualized cardiac resynchronization therapy:rationale and design of the adaptive cardiac resynchronization therapy trial. Am Heart J. 2012;163:747-52.
 
2) Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing:analysis of the adaptive CRT trial. Heart Rhythm. 2013;10:1368-74.
PubMed
P.207 掲載の参考文献
1) Kurzidim K, Reinke H, Sperzel J, et al. Invasive optimization of cardiac resynchronization therapy:role of sequential biventricular and left ventricular pacing. Pacing Clin Electrophysiol. 2005;28:754-61.
PubMed
2) Khaykin Y, Exner D, Birnie D, et al. Adjusting the timing of left-ventricular pacing using electrocardiogram and device electrograms. Europace. 2011;13:1464-70.
PubMed
3) Jones RC, Svinarich T, Rubin A, et al. Optimal atrioventricular delay in CRT patients can be approximated using surface electrocardiography and device electrograms. J Cardiovasc Electrophysiol. 2010;21:1226-32.
PubMed
4) Martin DO, Lemke B, Birnie D, et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy:results of the adaptive CRT trial. Heart Rhythm. 2012;9:1807-14.
PubMed
P.214 掲載の参考文献
1) Slotwiner D, Varma N, Akar JA, et al. HRS expert consensus statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm. 2015;12:e69-100.
 
P.216 掲載の参考文献
1) Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy(MADIT-CRT)trial. Circulation. 2011;123:1159-66.
PubMed
2) Thebault C, Donal E, Meunier C, et al. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. European Heart Journal. 2012;33:2662-71.
PubMed
3) Gold MR, Birgersdotter-Green U, Singh JP, et al. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. European Heart Journal. 2011;32:2516-24.
PubMed
P.217 掲載の参考文献
1) Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy:the TARGET study:a randomized, controlled trial. J Am Coll Cardiol. 2012;17:1509-18.
PubMed
2) Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy:results of the speckle tracking assisted resynchronization therapy for electrode region trial. Circ Heart Fail. 2013;6:427-34.
PubMed
3) Marek JJ, Saba S, Onishi T, et al. Usefulness of echocardiographically guided left ventricular lead placement for cardiac resynchronization therapy in patients with intermediate QRS width and non-left bundle branch block morphology. Am J Cardiol. 2014;113:107-16.
PubMed
4) Singh JP, Fan D, Heist EK, et al. Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. Heart Rhythm. 2006;3:1285-92.
PubMed
5) Sharma PS, Huizar J, Ellenbogen KA, et al. recruitment of bundle branches with permanent his bundle pacing in a patient with advanced conduction system disease:what is the mechanism? Heart Rhythm. 2016;13:623-5.
 
P.220 掲載の参考文献
1) 石川利之, 中島 博, 編. 心臓デバイス植込み手技. 東京:南江堂;2011. p.22-37.
 
P.223 掲載の参考文献
1) Russo V, De Crescenzo I, Ammendola E, et al. Coronary sinus spasm during left ventricular lead implantation for biventricular pacing. Europace:2007;9:528-30. Epub 2007/05/18.
 
2) Woollett IF, Pinney S, Magnano AR. Images in cardiovascular medicine. Balloon dilatation of coronary sinus spasm during placement of a biventricular pacing lead. Circulation. 2005;111:e304-5. Epub 2005/05/25.
 
P.225 掲載の参考文献
1) Russo V, De Crescenzo I, Ammendola E, et al. Coronary sinus spasm during left ventricular lead implantation for biventricular pacing. Europace. 2007;9:528-30.
PubMed
2) Woollett IF, Pinney S, Magnano RA. Balloon dilatation of coronary sinus spasm during placement of a biventricular pacing lead. Circulation. 2005, 111:e304-5.
 
3) Ellis CR, Jongnarangsin K. Successful left ventricular lead implantation following intracoronary sinus nitroglycerin for isolated lateral coronary sinus branch venous spasm. J Innov Cardiac Rhythm Manage. 2010;1:91-3.
 
P.230 掲載の参考文献
1) Ritter P, Daubert C, Mabo P, et al. Haemodynamic benefit of a rate-adapted A-V delay in dual chamber pacing. European Heart Journal. 1989;10:637-46. Epub 1989/07/01.
 
2) Ishikawa T, Sugano T, Sumita S, et al. Relationship between atrioventricular delay, QT interval and cardiac function in patients with implanted DDD pacemakers. Europace:European pacing, arrhythmias, and cardiac electrophysiology:journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 1999;1:192-6. Epub 2001/02/28.
 
P.231 掲載の参考文献
1) Ishikawa T, Sumita T, Kimura K, et al. Prediction of optimal atrioventricular delay in patients with implanted DDD pacemakers. Pacing Clin Electrophysiol. 1999;22:2078-84.
 

第2章 応用編 - ICD・CRTをより賢く使う -

P.246 掲載の参考文献
1) 日本循環器学会合同研究班報告. 不整脈の非薬物療法ガイドライン. 2011年改訂版<http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf>.
 
2) Goldstein S, Landis JR, Leighton R, et al. Predictive survival models for resuscitated victims of out-of-hospital cardiac arrest with coronary heart disease. Circulation. 1985;71:873-80.
PubMed
3) The antiarrhythmics versus implanted defibrillators(AVID)investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients with resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-83.
 
4) Domanski MJ, Sakseena S, Epsein S, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol. 1999;34:1090.
 
5) Connoly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study(CIDS). A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-302.
 
6) Sheldon R, Connoly SJ, Krahn A, et al. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy. The Canadian implantable defibrillator study. Circulation. 2000;101:1660-4.
 
7) Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg(CASH). Circulation. 2000;102:748-54.
PubMed
8) Conolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8.
 
9) Moss AJ, Hall J, Cannom DS, et al. Improved survival with an implanted defibrillaton in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial(MADIT)Investigators. N Engl J Med. 1996;335:1933-40.
 
10) Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2001;346:877-83.
 
11) Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882-90.
 
12) Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
 
13) Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-8.
 
14) Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defobrollator after acute myocardial infarction. N Engl J Med. 2004;351:2481-8.
PubMed
15) Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427-36.
PubMed
16) Pouleur AC, Barkoudah E, Uno H, et al. Pathogenesis of sudden unexplained death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, hear failure, or both. Circulation. 2010;122:597-602.
PubMed
17) Sjoblom J, Muhrbeck J, Witt N, et al. Evolution of left ventricular ejection fraction after acute myocardial infarction:implications for implantable cardioverter-defibrillator eligibility. Circulation. 2014;130:743-8.
PubMed
18) Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era:the healing and early afterload reducing therapy study. Ann Intern Med. 2001;134:451-8.
PubMed
19) Winther-Jensen M, Kjaergaard J, Lassen JF, et al. Implantable cardioverter defibrillator and survival after out-of-hospital cardiac arrest due to acute myocardial infarction in Denmark in the years 2001-2012, a nationwide study. Eur Heart J Acute Cardiovasc Care. 2017;2048872616687115.
PubMed
20) Masuda M, Nakatani D, Hikoso S, et al. Clinical impact of ventricular tachycardia and/or fibrillation during the acute phase of acute myocardial infarction on inhospital and 5-year mortality rates in the percutaneous coronary intervention era. Circ J. 2016;80:1539-47.
PubMed
21) Daubert JP, Zareba W, Hall WJ, et al. Predictive value of ventricular arrhythmia inducibility for subsequent venricular tachycardia or ventricular fibrillation in multicenter automatic defibrillator implantation trial(MADIT)II patient. J Am Coll Cardiol. 2006;47:98-107.
 
22) Bigger JT, for the coronary artery bypass graft(CABG)patch trial investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997;337:1569-75.
 
23) Goldenberg I, Vyas AK, Hall J, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288-96.
 
24) Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term(8-year)benefit of the implantable cardioverterdefibrillator. J Am Coll Cardiol. 2012;59:2075-9.
 
25) Satake H, Fukuda K, Sakata Y, et al. Current status of prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronicheart failure. -A report from the CHART-2 study. Circ J. 2015;79:381-90.
 
26) Shimizu A, Nitta T, Kurita T, et al. Actual condition of implantable defibrillation therapy over 5 years in Japan. Arrhytmia. 2012;28:263-72.
 
27) Pokorney S, Miller AL, Chen AY, et al. Implantable cardiverter-defibrillator use among medicare patients with ow ejection fraction after acute myocardial infarction. JAMA. 2015;313:2433-40.
 
28) Chen CY, Stevenson LW, Stewart GC, et al. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other co-morbidities:cohort study of older patients with heart failure. BMJ. 2015;351:h3529.
PubMed
29) Meisel SR, Mazur A, Chetboun I, et al. Usefulness of implantable cardioverterdefibrillators in refractory variant angina pectoris complicated by ventricular fibrillation in patients with angiographically normal coronary arteries. Am J Cardiol. 2002;89:1114-6.
PubMed
30) Takagi Y, Yasuda S, Tsunoda R, et al. Japanese Coronary Spasm Association. Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest:multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol. 2011;4:295-302.
PubMed
31) Takagi Y, Takahashi J, Yasuda S, et al. Prognostic stratification of patients with vasospastic angina:a comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. J Am Coll Cardiol. 2013;62:1144-53.
PubMed
32) Sato A, Tanabe Y, Chinushi M, et al. Analysis of J waves during myocardial ischemia. Europace. 2012;14:715-23.
PubMed
33) Fumimoto T, Ueyama T, Shimizu A, et al. Inferior J waves in patients with vasospastic angina mighy be a risk factor for ventricular fibrillation. J Cardiol. 2017 in press.
 
34) 日本循環器学会合同研究班報告:冠攣縮性狭心症の診断と治療に関するガイドライン(2013年改訂版). <http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawah_h.pdf>
 
35) Shiga T, Hagiwara N, Ogawa H, et al. Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era:results from the HIJAMI-II registry. Heart. 2009;95:216-20.
PubMed
36) Kuga K, Yamasaki H, Hattori A, et al. Prognosis of myocardial infarction with left ventricular dysfunction in the coronary revascularization era. -Subanalysis of the Japanese Coronary Artery Disease(JCAD) Study-. Circ J. 2014;78:2483-91.
PubMed
37) Shimizu A, Mitsuhashi T, Nitta T, et al. Japan implantable devices in coronary artery disease(JID-CAD)study design. J Arrhythm. 2015;31:83-7.
PubMed
P.257 掲載の参考文献
1) Kadish A, Dyer A, Daubert JP, et al. Defibrillators in non-ischemic cardiomyopathy treatment evaluation I. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8.
PubMed
2) Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial I. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
PubMed
3) Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy:a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874-9.
PubMed
4) Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221-30.
PubMed
5) Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy:systematic review and meta-analysis. JACC Heart Fail. 2016.
 
6) Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients:data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator(WEARIT-II Registry). Circulation. 2015;132:1613-9.
PubMed
7) Group JCSJW. Guidelines for non-pharmacotherapy of cardiac arrhythmias(JCS 2011). Circ J. 2013;77:249-74.
PubMed
8) Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-12.
PubMed
9) O'Mahony C, Jichi F, Pavlou M, et al. Hypertrophic cardiomyopathy outcomes I. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy(HCM risk-SCD). Eur Heart J. 2014;35:2010-20.
 
10) Authors/Task Force m, Elliott PM, Anastasakis A, et al, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology(ESC). Eur Heart J. 2014;35:2733-79.
 
11) Quin EM, Cuoco FA, Forcina MS, et al. Defibrillation thresholds in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011;22:569-72.
PubMed
12) Epstein LM, Love CJ, Wilkoff BL, et al. Superior vena cava defibrillator coils make transvenous lead extraction more challenging and riskier. J Am Coll Cardiol. 2013;61:987-9.
PubMed
13) Okamura H, Friedman PA, Inoue Y, et al. Single-coil defibrillator leads yield satisfactory defibrillation safety margin in hypertrophic cardiomyopathy. Circ J. 2016;80:2199-203.
PubMed
14) Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis:role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43-8.
PubMed
15) Ise T, Hasegawa T, Morita Y, et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart. 2014;100:1165-72.
PubMed
16) McGarry TJ, Narayan SM. Defining arrhythmic risk and defibrillator therapy in ARVC:shocking rhythm? J Am Coll Cardiol. 2014;64:126-8.
PubMed
17) Gallego P, Gonzalez AE, Sanchez-Recalde A, et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol. 2012;110:109-17.
PubMed
18) Henmi R, Ejima K, Yagishita D, et al. Long-term efficacy of implantable cardioverter defibrillator in repaired tetralogy of Fallot-role of anti-tachycardia pacing. Circ J. 2017;81:165-71.
PubMed
P.281 掲載の参考文献
1) HRS/EHRS/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. 2013;p.6-7.
 
2) Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome:consensuss report. Circulation. 2002, 106:2514-9.
 
3) Antzelevitch C, Yan GX, Ackerman MJ, et al. J-Wave syndrome expert consensuss conference report:Emerging concepts and gaps in knowledge. Arrhythmia. 2017;19:665-94.
 
4) Tokioka K, Kusano KF, Morita H, et al. Electrocardiographic Parameters and Fatal Arrhythmic Events in Patients With Brugada Syndrome Combination of Depolarization and Repolarization Abnormalities. JACC. 2014;63:2131-8.
PubMed
5) Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a Marker of Conduction Abnormality and a Predictor of Prognosis of Brugada Syndrome. Circulation. 2008;118:1697-704.
 
6) Kusano KF, Taniyama M, Nakamura K, et al. Atrial Fibrillation in Patients with Brugada syndrome. JACC. 2008;51:1169-75.
PubMed
7) Maury P, Rollin A, Sacher F, et al. Prevalence and prognostic role of various conduction disturbances in patients with the Brugada syndrome. Am J Cardiol. 2013;112:1384-9.
PubMed
8) Take Y, Morita H, Toh N, et al. Identification of high-risk syncope related to ventricular fibrillation in patients with Brugada syndrome. Heart Rhythm. 2012;9:752-9.
PubMed
9) Sacher F, Probst V, Maury P, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome -A multicenter Study. Circulation. 2006;114:2317-24.
PubMed
10) 日本循環器学会, 他(班長:奥村 謙). 不整脈の非薬物治療ガイドライン(2011年改訂版). 2011;p.24.
 
11) Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome:results of the PRELUDE(PRogrammed ELectrical stimulation preDictive valuE)registry. J Am Coll Cardiol. 2012;59:37-45.
PubMed
12) Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome:results from the FINGER Brugada Syndrome Registy. Circulation. 2010;121:635-43.
 
13) Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008;358:2016-23.
PubMed
14) Kamakura T, Wada M, Ishibashi K, et al. Differences in the onset mode of ventricular tachyarrhythmia between patients with J wave in anterior leads versus inferolateral leads. Heart Rhythm. 2016;0:1-9.
 
15) C. Antzelevitch, Yan GX, Ackerman MJ, et al. J-Wave syndrome expert consensus conferenece report:Emerging concepts and gaps in knowledge. J Arrhythm. 2016;32:315-39.
 
16) Junttila MJ, Sager SJ, Freiser M, et al. Inferolateral early repolarization in athletes. J Interv Card Electrophysiol. 2011;31:33-8.
PubMed
17) Gourraud JB, Le Scouarnec S, Sacher F, et al. Identification of large families in early repolarization syndrome. J Am Coll Cardiol. 2013;61:164-72.
PubMed
18) Priori SG, Wilde AA, Horie M, et al. Executive Summary:HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm. 2013.
 
19) Antzelevitch C, Yan GX, Ackerman MJ, et al. J-Wave syndromes expert consensus conference report:Emerging concepts and gaps in knowledge. J Arrhythm. 2016;32:315-39.
PubMed
20) Bertomeu-Gonzalez V, Ruiz-Granell R, Garcia-Civera R, et al. Syncopal monomorphic ventricular tachycardia with pleomorphism, sensitive to antitachycardia pacing in a patient with Brugada syndrome. Europace. 2006;8:1048-50.
 
21) Braunwald's heart disease 10th edition 32. Genetics of Cardiac Arrhythmias. Elsevier Saunders. 2014. p.617-27.
 
22) Schwartz PJ, Stramba-Badiale M, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120:1761-7.
PubMed
23) 青沼和隆, 他. QT延長症候群(先天性・二次性)とBrugada症候群の診療に関するガイドライン. 日本循環器学会. 2007;p.23.
 
24) Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome. gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89-95.
 
25) Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866-74.
 
26) Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD. True or false? Heart Rhythm. 2009;6:113-20.
PubMed
27) Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2. higher recurrence of events under metoprolol. J Am Coll of Cardiol. 2012;60:2092-9.
PubMed
28) Ackerman MJ, Priori SG, Dubin AM, et al. Beta blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Are all beta blockers equivalent? Heart Rhythm. 2016.
PubMed
29) Wilde AMAK ES, Shimizu W, Peterson DR, et al. Clinical aspects of Type 3 Long QT Syndrome, an international multicenter study. Circulation. 2016.
 
30) Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the Long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happen to them? Data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator Registry, Circulation. 2010;122:1272-82.
 
31) Gussak I, Brugada P, Brugada J, et al. Idiopathtic short QT interval;a new clinical syndrome? Cardiology. 2000;94:99-102.
PubMed
32) Algra A, Tijssen JG, Roelandt JR. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J. 1993;70:43-8.
PubMed
33) Gaita F, Giustetto C, Bianchi F. Short QT syndrome:A familial cause of sudden death. Circulation. 2003;108:965-70.
PubMed
34) Priori SG, Wilde AA, Horie M, et al. HRS/EHRS/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm. 2013;10:1932-63.
 
35) Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005;16:54-8.
PubMed
36) Anttonen O, Junttila MJ, Maury P, et al. Differences in twelve-lead electrocardiogram between symptomatic and asymptomatic subjects with short QT interval. Heart Rhythm. 2009;6:267-71.
PubMed
37) Mazzanti A, Kanthan A, Monteforte N, et al. Novel insights in the natural history of short QT syndrome. J Am Coll Cardiol. 2013;63:1300-8.
PubMed
38) Passman R. Inappropriate implantable cardioverter defibrillator therapy in the short QT syndrome;old problem in a new disease. J Cardiovasc Electrophysiol. 14:1278-9, 2003.
 
39) Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Europace. 2013;15:1389-406.
PubMed
40) Krahn AD, Healey JS, Chauhan V, et al. Systematic assessment of patients with unexplained cardiac arrest;cardiac arrest survivors with preserved ejection fraction registry(CASPER). Circulation. 2009;120:278-85.
PubMed
41) Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society(HRS) and the European Heart Rhythm Association(EHRA). Heart Rhythm. 2011;8:1308-39.
PubMed
42) Priori SG, Wilde AA, Horie M, et al. HRS/EHRS/APHRS Expert Consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932-63.
 
43) Priori SG, Napolitano C, Memmi M, et al. A Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69-74.
PubMed
44) Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380-3.
PubMed
45) Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmia and the prevention of sudden cardiac death. The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Societyof Cardiology(ESC).
 
46) Roses-Noguer F, Jarman JW, Clague JR, et al. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2014;11:58-66.
PubMed
P.293 掲載の参考文献
1) Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II. J Am Coll Cardiol. 2008;51:1357-65.
 
2) Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009-17.
PubMed
3) Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275-83.
PubMed
4) Gilliam III FR, Hayes DL, Boehmer JP, et al. Real world evaluation of dual-zone ICD and CRT-D programing compared to single-zone programming:The ALTITUDE REDUCED study. J Cardiovasc Electrophysiol. 2011;22:1023-9.
 
5) Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients. Results from the PREPARE(Primary Prevention Parameters Evaluation)study. J Am Coll Cardiol. 2008;52:541-50.
PubMed
6) Gasparini M, Proclemer A, Klersy C, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery. The ADVANCE III randomized clinical trial. JAMA. 2013;309:1903-11.
PubMed
P.306 掲載の参考文献
1) Gottipaty VK, Krelis SP, Lu F, et al. The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure. J Am Coll Cardiol. 1999;33:145A.
 
2) Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation. 2004;109:1133-9.
PubMed
3) Bakker PF, Meijburg H, de Jonge N, et al. Beneficial effects of biventricular pacing in congestive heart failure. Pacing Clin Electrophysiol. 1994;17:820A.
 
4) Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol. 1994;17:1974-9.
PubMed
5) Daubert JC, Ritter P, Le Breton H, et al. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing Clin Electrophysiol. 1998;21:239-45.
PubMed
6) Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-53.
PubMed
7) Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
 
8) Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.
PubMed
9) Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-43.
PubMed
10) Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.
PubMed
11) Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mildto-moderate heart failure. N Engl J Med. 2010;363:2385-95.
 
12) Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy:the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology(ESC). Developed in collaboration with the European Heart Rhythm Association(EHRA). Eur Heart J. 2013;34:2281-329.
 
13) Yancy CW, Jessup M, Bozkurt B, et al. 2013. ACCF/AHA guideline for the management of heart failure. a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239.
 
14) Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395-405.
PubMed
15) Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC. Eur Heart J. 2016;37:2129-200.
 
16) Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy:a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2013;61:1318-68.
 
17) Shimizu A, Nitta T, Kurita T, et al. Current status of implantable defibrillator devices in patients with left ventricular dysfunction-The first report from the online registry database. J Arrhythmia. 2008;24:133-40.
 
18) Yokoshiki H, Shimizu A, Mitsuhashi T, et al. Trends and determinant factors in the use of cardiac resynchronization therapy devices in Japan:Analysis of the Japan cardiac device treatment registry database. J Arrhythm. 2016;32:486-90.
PubMed
19) Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002;105:438-45.
PubMed
20) Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation. 2000;102:3053-9.
PubMed
21) Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT(PROSPECT) trial. Circulation. 2008;117:2608-16.
PubMed
22) Barsheshet A, Goldenberg I, Moss AJ, et al. Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J. 2011;32:1622-30.
PubMed
23) Goldenberg I, Moss AJ, Hall WJ, et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy(MADIT-CRT). Circulation. 2011;124:1527-36.
PubMed
24) Ruwald MH, Solomon SD, Foster E, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes:results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy(MADIT-CRT) trial. Circulation. 2014;130:2278-86.
PubMed
25) Gasparini M, Mantica M, Galimberti P, et al. Is the outcome of cardiac resynchronization therapy related to the underlying etiology? Pacing Clin Electrophysiol. 2003;26:175-80.
 
26) St John Sutton M, Ghio S, Plappert T, et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120:1858-65.
 
27) St John Sutton M, Plappert T, Hilpisch KE, et al. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology:quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation(MIRACLE). Circulation. 2006;113:266-72.
 
28) Wikstrom G, Blomstrom-Lundqvist C, Andren B, et al. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CAREHF trial. Eur Heart J. 2009;30:782-8.
PubMed
29) Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure:the MIRACLE ICD Trial. JAMA. 2003;289:2685-94.
PubMed
30) Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547-56.
PubMed
31) Witt CT, Kronborg MB, Nohr EA, et al. Adding the implantable cardioverterdefibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy. Europace. 2016;18:413-9.
 
32) Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011;57:2416-23.
PubMed
33) Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.
 
34) Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
PubMed
35) Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy:the Cardiomyopathy Trial(CAT). Circulation. 2002;105:1453-8.
PubMed
36) Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-12.
PubMed
37) Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8.
PubMed
38) Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
 
39) Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221-30.
PubMed
40) Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy(MADIT-CRT)trial. Circulation. 2011;123:1159-66.
PubMed
41) Bleeker GB, Kaandorp TA, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation. 2006;113:969-76.
PubMed
42) Delgado V, van Bommel RJ, Bertini M, et al. Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict longterm survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation. 2011;123:70-8.
PubMed
43) Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy:the TARGET study:a randomized, controlled trial. J Am Coll Cardiol. 2012;59:1509-18.
PubMed
44) Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy:results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ Heart Fail. 2013;6:427-34.
PubMed
45) Abu Daya H, Alam MB, Adelstein E, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy in ischemic vs nonischemic cardiomyopathy patients. Heart Rhythm. 2014;11:614-9.
PubMed
46) Roque C, Trevisi N, Silberbauer J, et al. Electrical storm induced by cardiac resynchronization therapy is determined by pacing on epicardial scar and can be successfully managed by catheter ablation. Circ Arrhythm Electrophysiol. 2014;7:1064-9.
PubMed
47) Marsan NA, Bleeker GB, Van Bommel RJ, et al. Cardiac resynchronization therapy in patients with ischemic versus non-ischemic heart failure:Differential effect of optimizing interventricular pacing interval. Am Heart J. 2009;158:769-76.
PubMed
48) Forleo GB, Santini L, Giammaria M, et al. Multipoint pacing via a quadripolar leftventricular lead:preliminary results from the Italian registry on multipoint leftventricular pacing in cardiac resynchronization therapy(IRON-MPP). Europace. 2017;19:1170-7.
 
49) Pappone C, Calovic Z, Vicedomini G, et al. Improving cardiac resynchronization therapy response with multipoint left ventricular pacing:Twelve-month follow-up study. Heart Rhythm. 2015;12:1250-8.
PubMed
50) Zanon F, Marcantoni L, Baracca E, et al. Optimization of left ventricular pacing site plus multipoint pacing improves remodeling and clinical response to cardiac resynchronization therapy at 1 year. Heart Rhythm. 2016;13:1644-51.
PubMed
51) Sohal M, Shetty A, Niederer S, et al. Mechanistic insights into the benefits of multisite pacing in cardiac resynchronization therapy:The importance of electrical substrate and rate of left ventricular activation. Heart Rhythm. 2015;12:2449-57.
PubMed
52) Umar F, Taylor RJ, Stegemann B, et al. Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar:the MAESTRO study. Europace. 2016;18:1227-34.
 
P.322 掲載の参考文献
1) Wang NC, Maggioni AP, Konstam MA, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008;299:2656-66.
PubMed
2) Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547-56.
PubMed
3) Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-53.
PubMed
4) Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
 
5) Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-43.
PubMed
6) Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.
PubMed
7) Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007;357:2461-71.
PubMed
8) Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395-405.
PubMed
9) Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547-56.
PubMed
10) 不整脈の非薬物治療ガイドライン(2011年改訂版). 日本循環器学会. 2011.
 
11) Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327.
 
12) Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC. Eur Heart J. 2016;37:2129-200.
 
13) Brignole M, Botto G, Mont L,et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation:a randomized trial. Eur Heart J. 2011;32:2420-9.
PubMed
14) Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
PubMed
15) Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-8.
PubMed
16) Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8.
PubMed
17) Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction:Bayesian network meta-analysis of randomised controlled trials. BMJ 2007;335:925.
PubMed
18) Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
 
19) Kober L, Thune JJ, Nielsen JC. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221-30.
PubMed
20) van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks:incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011;57:556-62.
PubMed
21) Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations:an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35:1186-94.
PubMed
P.329 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン(2010年度合同研究班報告). 不整脈の非薬物治療ガイドライン(2011年改訂版). 日本循環器学会. 2011.
 
2) Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverterdefibrillators and cardiac resynchronization therapy:a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2013;61:1318-68.
 
3) Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease athigh risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.
 
4) Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
PubMed
5) Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882-90.
 
6) Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial(SCD-HeFT)Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
 
7) Kadish A, Dyer A, Daubert JP, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation(DEFINITE)Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8.
PubMed
8) Hess PL, Al-Khatib SM, Han JY, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients:does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes. 2015;8:179-86.
PubMed
9) Hernandez AF, Fonarow GC, Hammill BG, et al. Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. Circ Heart Fail. 2010;3:7-13.
PubMed
10) Huang DT, Sesselberg HW, McNitt S, et al. MADIT-II Research Group. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function:a MADIT-II substudy. J Cardiovasc Electrophysiol. 2007;18:833-8.
 
11) Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis:age and effectiveness of prophylactic implantable cardioverter defibrillators. Ann Intern Med. 2010;153:592-9.
PubMed
12) Kong MH, Al-Khatib SM, Sanders GD, et al. Use of implantable cardioverter-defibrillators for primary prevention in older patients:a systematic literature review and meta-analysis. Cardiol J. 2011;18:503-14.
PubMed
13) Brullmann S, Dichtl W, Paoli U, et al. Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients aged >= 75 years versus those < 75 years. Am J Cardiol. 2012;109:712-7.
PubMed
14) Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices):developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350-408.
 
15) Barra S, Providencia R, Paiva L, et al. Implantable cardioverter-defibrillators in the elderly:Rationale and specific age-related considerations. Europace. 2015;17:174-86.
PubMed
16) Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239.
 
17) Bleeker GB, Schalij MJ, Molhoek SG, et al. Comparison of effectiveness of cardiac resynchronization therapy in patients < 70 versus > or = 70 years of age. Am J Cardiol. 2005;96:420-2.
PubMed
18) Penn J, Goldenberg I, Moss AJ, et al. MADIT-CRT Trial investigators. Improved outcome with preventive cardiac resynchronization therapy in the elderly:a MADIT-CRT substudy. J Cardiovasc Electrophysiol. 2011;22:892-7.
 
19) Fumagalli S, Valsecchi S, Boriani G, et al. Comparison of the usefulness of cardiac resynchronization therapy in three agegroups( <65, 65-74 and >= 75 Years)(from the InSync/InSync ICD Italian Registry). Am J Cardiol. 2011;107:1510-6.
PubMed
20) Khazanie P, Hammill BG, Qualls LG, et al. Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure:analysis of the ICD Registry and ADHERE. Circ Heart Fail. 2014;7:926-34.
PubMed
21) Verbrugge FH, Dupont M, De Vusser P, et al. Response to cardiac resynchronization therapy in elderly patients( >= 70 years) and octogenarians. Eur J Heart Fail. 2013;15:203-10.
PubMed
22) Adelstein EC, Liu J, Jain S, et al. Clinical outcomes in cardiac resynchronization therapy-defibrillator recipients 80 years of age and older. Europace. 2016;18(3):420-7.
PubMed
P.340 掲載の参考文献
1) Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-53.
PubMed
2) Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
 
3) Achilli A, Peraldo C, Sassara M, et al. Prediction of response to cardiac resynchronization therapy:the selection of candidates for CRT(SCART)study. Pacing Clin Electrophysiol. 2006;29 Suppl 2:S11-9.
 
4) Group JCSJW. Guidelines for non-pharmacotherapy of cardiac arrhythmias(JCS 2011). Circ J. 2013;77:249-74.
PubMed
5) Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy(MADIT-CRT) trial. Circulation. 2011;123(11):1159-66.
PubMed
6) Thebault C, Donal E, Meunier C, et al. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012;33:2662-71.
PubMed
7) Calo L, Martino A, de Ruvo E, et al. Acute echocardiographic optimization of multiple stimulation configurations of cardiac resynchronization therapy through quadripolar left ventricular pacing:a tailored approach. Am Heart J. 2014;167:546-54.
 
8) Kamath GS, Cotiga D, Koneru JN, et al. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. J Am Coll Cardiol. 2009;53(12):1050-5.
PubMed
9) Yoshida K, Seo Y, Yamasaki H, et al. Effect of triangle ventricular pacing on haemodynamics and dyssynchrony in patients with advanced heart failure:a comparison study with conventional bi-ventricular pacing therapy. Eur Heart J. 2007;28:2610-9.
PubMed
10) Leclercq C, Gadler F, Kranig W, et al. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure. J Am Coll Cardiol. 2008;51:1455-62.
PubMed
11) Lenarczyk R, Kowalski O, Kukulski T, et al. Mid-term outcomes of triple-site vs. conventional cardiac resynchronization therapy:a preliminary study. Int J Cardiol. 2009;133:87-94.
PubMed
12) Pappone C, Calovic Z, Vicedomini G, et al. Multipoint left ventricular pacing improves acute hemodynamic response assessed with pressure-volume loops in cardiac resynchronization therapy patients. Heart Rhythm. 2014;11:394-401.
PubMed
13) Pappone C, Calovic Z, Vicedomini G, et al. Improving cardiac resynchronization therapy response with multipoint left ventricular pacing:Twelve-month follow-up study. Heart Rhythm. 2015;12:1250-8.
PubMed
14) Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing:analysis of the adaptive CRT trial. Heart Rhythm. 2013;10:1368-74.
PubMed
P.351 掲載の参考文献
1) Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber(DDD)pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90:2731-42.
PubMed
2) Kappenberger LJ, Linde C, Jeanrenaud X, et al. Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy(PIC)Study Group. Europace. 1999;1:77-84.
 
3) Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dualchamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study(M-PATHY). Circulation. 1999;99:2927-33.
PubMed
4) Rinaldi CA, Bucknall CA, Gill JS. Beneficial effects of biventricular pacing in a patient with hypertrophic cardiomyopathy and intraventricular conduction delay. Heart. 2002;87:e6.
 
5) Komsuoglu B, Vural A, Agacdiken A, et al. Effect of biventricular pacing on left ventricular outflow tract pressure gradient in a patient with hypertrophic cardiomyopathy and normal interventricular conduction. J Cardiovasc Electrophysiol. 2006;17:207-9.
 
6) Lenarczyk R, Kowalski O, Kukulski T, et al. Resynchronization or dyssynchronization--successful treatment with biventricular stimulation of a child with obstructive hypertrophic cardiomyopathy without dyssynchrony. J Cardiovasc Electrophysiol. 2007;18:542-4.
 
7) Berruezo A, Vatasescu R, Mont L, et al. Biventricular pacing in hypertrophic obstructive cardiomyopathy:a pilot study. Heart Rhythm. 2011;8:221-7.
PubMed
8) Berruezo A, Penela D, Burgos F, et al. Optimized pacing mode for hypertrophic cardiomyopathy:Impact of ECG fusion during pacing. Heart Rhythm. 2015;12:909-16.
PubMed
9) Lenarczyk R, Wozniak A, Kowalski O, et al. Effect of cardiac resynchronization on gradient reduction in patients with obstructive hypertrophic cardiomyopathy:preliminary study. Pacing Clin Electrophysiol. 2011;34:1544-52.
PubMed
10) Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology(ESC). Eur Heart J. 2014;35:2733-79.
 
11) 日本循環器学会学術委員会合同研究班:肥大型心筋症の診療に関するガイドライン(20012年改訂版).<http://www.j-circ.or.jp/guideline/pdf/JCS2012_doi_h.pdf>
 
12) Giraldeau G, Duchateau N, Bijnens B, et al. Dyssynchronization reduces dynamic obstruction without affecting systolic function in patients with hypertrophic obstructive cardiomyopathy:a pilot study. Int J Cardiovasc Imaging. 2016;32:1179-88.
PubMed

第3章 特別編 - 知って使う新しい除細動器 ( 脱静脈内除細動リードシステム ) -

P.362 掲載の参考文献
1) Eisenberg MS. Life in the Balance:Emergency Medicine and the Quest to Reverse Sudden Death. Oxford University Press, New York, 1997.
 
2) Jaggarao NS, Heber M, Grainger R, et al. Use of an automated external defibrillator-pacemaker by ambulance staff. Lancet. 1982;2(8289):73-5.
PubMed
3) Page RL, Joglar JA, Kowal RC, et al. Use of automated external defibrillators by a U.S. airline. N Engl J Med. 2000;343:1210-6.
 
4) Valenzuela TD, Roe DJ, Nichol G, et al. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med. 2000;343:1206-9.
PubMed
5) 日本循環器学会. 自動体外式除細動器(AED)検討委員会報告書. 日本における非医師へのAED導入実施に向けた検討報告. Circ J 2002;66(Suppl IV):1419-36.
 
6) Nishiyama T, Nishiyama A, Negishi M, et al. Diagnostic accuracy of commercially available automated external defibrillators. J Am Heart Assoc. 2015;4:e002465.
PubMed
7) 三田村秀雄:AEDの市民使用に関わる問題. In 樋口範雄, 岩田 太, 編. 生命倫理と法II. 東京:弘文堂;2007. p.55-74.
 
8) Mitamura H. Public access defibrillation:advances from Japan. Nat Clin Pract Cardiovasc Med. 2008;5:690-2.
PubMed
9) Kitamura T, Iwami T, Kawamura T, et al. Nationwide public-access defibrillation in Japan. N Engl J Med. 2010;362:994-1004.
PubMed
10) Kitamura T, Kiyohara K, Sakai T, et al. Public-access defibrillation and out-ofhospital cardiac arrest in Japan. N Engl J Med. 2016;375:1649-59.
 
11) 総務省消防庁. 平成29年版 救急・救助の現況. 2017.
 
12) Bardy GH, Lee KL, Mark DB, et al. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med. 2008;358:1793-804.
PubMed
13) 日本循環器学会AED検討委員会:AEDの具体的設置・配置基準に関する提言. 心臓. 2012;44:392-402.
Medical*Online
14) Mitamura H, Iwami T, Mitani Y, et al. Aiming for zero-deaths:prevention of sudden cardiac death in schools. Statement from the AED Committee of the Japanese Circulation Society. Circ J. 2015;79:1398-401.
PubMed
P.372 掲載の参考文献
1) Pedersen CT, NealKay G, Kalman J, et al. EHRA/HRS/APHRS ExpertConsensuson VentricularArrhythmias. Heart Rhythm. 2014;11(10):e166-96.
 
2) Piccini JP, Allen LA, Kudenchuk PJ, et al. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. A science advisory from the American Heart Association. Circulation. 2016;133(17):1715-27.
PubMed
3) Niwano S, Sekiguchi Y, Ishii Y, et al. The second statement of clinical use of WCD. Japanese Heart Rhythm Society. <http://jhrs.or.jp/pdf/statement201505_01.pdf>.
 
4) Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-8.
 
5) Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-8.
PubMed
6) Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427-36.
PubMed
7) Exner DV, Kavanagh KM, Slawnych MP, et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol. 2007;50:2275-84.
PubMed
8) Pouleur AC, Barkoudah E, Uno H, et al. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010;122:597-602.
PubMed
9) Epstein AE, Abraham WT, Bianco NR, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol. 2013;62:2000-7.
PubMed
10) Toda K, Mackenzie K, Mehra MR, et al. Revascularization in severe ventricular dysfunction(15% < OR = LVEF < OR = 30%):a comparison of bypass grafting and percutaneous intervention. Ann Thorac Surg. 2002;74:2082-7.
 
11) Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults:results from the National Cardiovascular Data Registry. Circulation. 2012;125:1501-10.
PubMed
12) Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2013;112:117-28.
 
13) Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221-30.
PubMed
14) Singh, M, Wang NC, Jain S, et al. Utility of the wearable cardioverter-defibrillator in patients with newly diagnosed cardiomyopathy:A decade-long single-center experience. J Am Coll Cardiol. 2015;66:2607-13.
PubMed
15) Klein HU, Meltendorf U, Reek S, et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator(WCD). Pacing Clin Electrophysiol, 2010;33:353-67.
PubMed
16) Gronda E, Bourge RC, Costanzo MR, et al. Heart rhythm considerations in heart transplant candidates and considerations for ventricular assist devices:International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant. 2006;25:1043-56.
PubMed
17) Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients:Data from the prospective registry of patients using the wearable cardioverter defibrillator(WEARIT-II Registry). Circulation. 2015;132:1613-9.
PubMed
P.382 掲載の参考文献
1) Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303:322-4.
PubMed
2) Parikshit S. Sharma, Kenneth A. Ellenbogen. Inside or Outside of the Heart. J American College Cardiol. 2016;68:19:8:2056-8.
PubMed
3) Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneouse implantable cardioverter-defibrillator. N Engl J Med. 2010;363:36-44.
 
4) McLeod CJ, Boersma L, Okamura H, et al. The subcutaneouse implantable cardioverter defibrillator:state-of-the-art review. Euro Heart J Advance Access Publishied. 2015.
 
5) Burke MC, Gold MR, Knight BP, et al. Safty and Efficacy of the Totally Subcutaneouse Implantable Defibrilator. J American College Cardio. 2016;65:16:1605-15.
 
6) Poole JE, Gold MR. Who should receive the subcutaneouse implanted defibrillator? The subcutaneouse implantable cardioverter defibrillator(ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol. 2013;6:1236-45.
 
7) Olde Nordkamp LRA, Brouwer TF, Barr C, et al. Inappropriate shock in the subcutaneouse ICD:incidence, predictors, and management. Int J Cardiol. 2015;195:126-33.
 

書評

最近チェックした商品履歴

Loading...